Avastin Biosimilar Phase III Data Will Support Extrapolation, Amgen Says

Amgen and Allergan reported positive Phase III data for a biosimilar version of Roche’s blockbuster cancer drug Avastin in lung cancer, and are hopeful the data will support extrapolation to Avastin’s many indications. https://www.pharmamedtechbi.com/Publications/The-Pink-Sheet-Daily/2015/9/23/Avastin-Biosimilar-Phase-III-Data-Will-Support-Extrapolation-Amgen-Says?elsca1=pdly&elsca2=rss&elsca3=